Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 25.2 EUR 2.19%
Market Cap: 834.9m EUR

Wall Street
Price Targets

MEDCL Price Targets Summary
Medincell SA

Wall Street analysts forecast MEDCL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MEDCL is 35.99 EUR with a low forecast of 27.27 EUR and a high forecast of 52.5 EUR.

Lowest
Price Target
27.27 EUR
8% Upside
Average
Price Target
35.99 EUR
43% Upside
Highest
Price Target
52.5 EUR
108% Upside
Medincell SA Competitors:
Price Targets
000423
Dong-E-E-Jiao Co Ltd
58% Upside
ORX
Orexo AB
13% Upside
MRK
Merck & Co Inc
5% Upside
4016
Middle East Pharmaceutical Industries Company SJSC
12% Upside
CURA
Curaleaf Holdings Inc
47% Upside
3613
Beijing Tong Ren Tang Chinese Medicine Co Ltd
34% Upside

Revenue
Forecast

Revenue Estimate
Medincell SA

For the last 6 years the compound annual growth rate for Medincell SA's revenue is 61%. The projected CAGR for the next 3 years is 78%.

61%
Past Growth
78%
Estimated Growth
Estimates Accuracy
-40%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Medincell SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat

Net Income
Forecast

Net Income Estimate
Medincell SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-21%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MEDCL's stock price target?
Price Target
35.99 EUR

According to Wall Street analysts, the average 1-year price target for MEDCL is 35.99 EUR with a low forecast of 27.27 EUR and a high forecast of 52.5 EUR.

What is Medincell SA's Revenue forecast?
Projected CAGR
78%

For the last 6 years the compound annual growth rate for Medincell SA's revenue is 61%. The projected CAGR for the next 3 years is 78%.

Back to Top